Neuroscience research has been revolutionized by the use of recombinant viral vector technology from the basic, preclinical and clinical levels. Currently, multiple recombinant viral vector types are employed with each having its strengths and weaknesses depending on the proposed application. Helper-dependent adenoviral vectors (HdAd) are emerging as ideal viral vectors that solve a major need in the neuroscience field: (1) expression of transgenes that are too large to be packaged by other viral vectors and (2) rapid onset of transgene expression in the absence of cytotoxicity. Here, we describe the methods for large-scale production of HdAd viral vectors for in vivo use with neurospecific transgene expression.
You may also like
Setting the Brain’s Internal Clock: A Single Neuron...
October 1, 2026Max Planck Florida Institute for Neuroscience
World-Class Research on Schizophrenia
October 1, 2026Max Planck Institute of Psychiatry
Remote-control in the cortex: How distant synapses are...
October 1, 2026Max Planck Institute for Brain Research
The brain predicts based on scale-free probability...
August 31, 2026Ernst Strüngmann Institute for Neuroscience
Huntington’s Disease: Targeted Light Pulses Improve...
July 30, 2026Max Planck Institute for Biological Intelligence
Erin Schuman receives Kavli Prize
June 25, 2026Max Planck Institute for Brain Research
